15.41  -1.76 (-10.25%)		06-01 16:00
Open: 16.51 High: 16.99 Volume: 18,291		Pre. Close: 17.17 Low: 15.41 Market Cap: 17(M)

Short term
Mid term
Targets	6-month :	20.44	1-year :	23.87
Resists	First :	17.5	Second :	20.44
Pivot price	15.12
Supports	First :	14.47	Second :	12.6
MAs	MA(5) :	16.32	MA(20) :	15.06
	MA(100) :	13.86	MA(250) :	9.5
MACD	MACD :	0.5	Signal :	0.4
%K %D	K(14,3) :	80.6	D(3) :	83.8
RSI	RSI(14): 52.5
52-week	High :	18.2	Low :	2.88

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PLRZ ] has closed below upper band by 44.2%. Bollinger Bands are 2.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	17 - 17.09	17.09 - 17.14
Low:	15.22 - 15.33	15.33 - 15.39
Close:	15.26 - 15.42	15.42 - 15.52

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.

Thu, 28 May 2026
Polyrizon Appoints Veteran Entrepreneur Ami Oren to Board of Directors - The Globe and Mail

Wed, 27 May 2026
Polyrizon (PLRZ) appoints entrepreneur Ami Oren as new Class I director - Stock Titan

Wed, 13 May 2026
Polyrizon (Nasdaq: PLRZ) signs first U.S. clinical site for NASARIX PL-14 allergy study - Stock Titan

Wed, 13 May 2026
Polyrizon Ltd. Signs Clinical Trial Agreement for NASARIXTM Allergy Blocker Study in Texas - Quiver Quantitative

Mon, 04 May 2026
[EFFECT] Polyrizon Ltd. SEC Filing - Stock Titan

Wed, 08 Apr 2026
Polyrizon raises $3.5M in stock sale for working capital - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	1 (M)
Held by Insiders	0.9 (%)
Held by Institutions	9.6 (%)
Shares Short	38 (K)
Shares Short P.Month	67 (K)

EPS	-4.91
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	13.05
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-29 %
Return on Equity (ttm)	-25.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.17
Qtrly Earnings Growth	0 %
Operating Cash Flow	-5 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-3.15
PEG Ratio	0
Price to Book value	1.18
Price to Sales	0
Price to Cash Flow	-6.37

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.